Dishman Carbogen Amcis Limited , a prominent player in the pharmaceutical industry, has announced a strategic move to simplify its corporate structure. The company has completed the merger of two of its material wholly-owned step-down subsidiaries in Switzerland, marking a significant step towards streamlining its operations.

Merger Details

The merger involves two entities:

Both companies are wholly-owned subsidiaries of CARBOGEN AMCIS Holding AG and material step-down subsidiaries of Dishman Carbogen Amcis Limited.

Business Operations

The merged entities share similar business activities:

• Trading of raw materials, intermediate and finished products for chemical and pharmaceutical industries
• Acquisition, investment, management, financing, and sale of assets
• Participation in domestic and foreign companies, particularly in the chemical and pharmaceutical sectors

Financial Implications

Both CASPAG and CAINAG reported nil turnover for the financial year ended March 31, 2025. The merger transaction does not involve any cash consideration or share exchange.

Rationale and Impact

The primary objective of this merger is to simplify the legal structure of the CARBOGEN AMCIS Group. This strategic move is expected to enhance operational efficiency and potentially reduce administrative overheads.

Dishman Carbogen Amcis Limited has confirmed that this merger will not affect its shareholding pattern. The company's equity structure remains unchanged.

Regulatory Compliance

The merger has received necessary regulatory approvals. As a related party transaction between two wholly-owned subsidiaries, it is exempted under Regulation 23(5)(c) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This corporate action reflects Dishman Carbogen Amcis Limited's approach to optimizing its global operations. By consolidating its Swiss subsidiaries, the company aims to position itself for potentially improved operational synergies in the pharmaceutical landscape.

Dishman Carbogen Amcis Limited has announced that its subsidiary, CARBOGEN AMCIS AG, has formed a strategic partnership with Celonic Group to develop a fully integrated Antibody-Drug Conjugate (ADC) platform. This collaboration aims to provide a comprehensive solution for ADC development and manufacturing, addressing a critical need in the biopharmaceutical sector.

Key Highlights of the Partnership

• Integrated Expertise: The alliance combines Celonic's advanced biologics capabilities with CARBOGEN AMCIS's expertise in payload synthesis, conjugation, and sterile fill-finish.
• Streamlined Process: The partnership aims to create a seamless, end-to-end platform for ADC innovators, potentially speeding up timelines and simplifying the supply chain.
• Comprehensive Services: The integrated offering includes cell line development, antibody production, payload and linker synthesis, ADC conjugation, and sterile fill-finish.

Strategic Implications

The collaboration between CARBOGEN AMCIS and Celonic Group is positioned to meet the rising demand for ADCs, particularly in targeted cancer treatments. By offering a single, coordinated platform from cell line to commercial fill-finish, the partnership aims to accelerate innovation and reduce complexity for their partners in the biopharmaceutical industry.

Executive Insights

Stephan Fritschi, CEO of Carbogen Amcis Group, stated, "The new targeted cancer treatments have fueled a rising demand for ADCs, and this alliance positions us to meet that demand with unmatched technical expertise and operational agility."

Arpit Vyas, Global Managing Director of Dishman and Carbogen Amcis Group, added, "For more than 2 decades now we've been the preferred partner for linker & payload development and until now, with customer supplied monoclonal antibodies, precise conjugation. We are excited that henceforth, through our partnership with Celonic, innovators will now get a seamless, end-to-end ADC path—from cell line to commercial fill-finish—under one coordinated platform."

Future Developments

CARBOGEN AMCIS is exploring capacity expansion, including the potential implementation of continuous-flow conjugation using custom micro-equipment skids. This innovation could further enhance the precision and efficiency of ADC production.

The strategic alliance between Dishman Carbogen Amcis's subsidiary and Celonic Group represents a significant development in the ADC space, potentially offering biopharmaceutical companies a more streamlined and efficient path from development to commercialization of these complex therapies.